TruSight Oncology Platform Reagents

These enrichment-based next-generation sequencing (NGS) reagents enable simultaneous analysis of DNA and RNA, and can cover a wide range of cancer variant types. This methodology provides laboratories with a deep view into the genetics of cancer.

• Accurate Results from Low-Quality Samples¹
  Enables variant detection with as little as 40 ng DNA and RNA input, maximizing the results from precious formalin-fixed, paraffin-embedded (FFPE) samples.
• Supports Comprehensive Coverage of Cancer-Related Variants
  Allows the assessment of multiple variant types in one assay using DNA and RNA which creates efficiencies in sample usage, time, and cost.

• Integrated, Streamlined Workflow
  DNA and RNA are prepared in parallel with an integrated workflow following DNA shearing/cDNA synthesis.
• Flexible Applications
  Enrichment-based workflow allows for a wide variety of content, input types, and applications.

See the Entire TruSight Oncology Product Family